{"version":"1.0","type":"link","title":"Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS).","author_name":"Li A 외","author_url":"https://prs-insight.online/author/Li%20A","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/98697","thumbnail_width":1200,"thumbnail_height":630}